Skip to main content

Advertisement

Table 1 FDA approved antibody-drug conjugates for B cell malignancies and multiple myeloma

From: Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma

ADC names Target Indications Dosage and schedule Year of approval
Brentuximab vedotin (Adcetrix®) CD30 R/R HL - 1.8 mg/kg (maximum 180 mg) - Every 3 weeks until disease progression or unacceptable toxicity 2011
Frontline stage III & IV HL (+ AVD) - 1.2 mg/kg (maximum 120 mg) combined with chemotherapy - Every 2 weeks until a maximum of 12 doses, disease progression, or unacceptable toxicity 2018
Post-ASCT consolidation for HL - 1.8 mg/kg (maximum 180 mg) - Initiate within 4–6 weeks post-ASCT or upon recovery from ASCT - Every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity 2015
R/R systemic ALCL - 1.8 mg/kg (maximum 180 mg) - Every 3 weeks until disease progression or unacceptable toxicity 2011
R/R PTCL (+ CHP) - 1.8 mg/kg (maximum 180 mg) combined with chemotherapy - Every 3 weeks with each cycle of chemotherapy for 6 to 8 doses 2018
R/R CTCL - 1.8 mg/kg (maximum 180 mg) - Every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity 2017
Inotuzumab ozogamicin (Besponsa®) CD22 R/R B-cell ALL - Cycle 1 (21 day-cycle): 1.8 mg/m2 [day 1 (0.8 mg/m2), day 8 (0.5 mg/m2), and day 15 (0.5 mg/m2)] - Subsequent cycles (28 day-cycle): 1) Patients who have achieved CR or CRi: 1.5 mg/m2 [day 1 (0.5 mg/m2), day 8 (0.5 mg/m2), and day 15 (0.5 mg/m2)] per cycle 2) Patients who have not achieved CR or CRi: repeat cycle 1 - Duration: 1) Patients proceeding to ASCT: 2 cycles 2) Patients not proceeding to ASCT: maximum 6 cycles 2017
Moxetumomab pasudotox (Lumoxiti®) CD22 R/R HCL - 0.04 mg/kg on days 1, 3, and 5 of each 28-day cycle. - Maximum of 6 cycles, disease progression, or unacceptable toxicity 2018
Polatuzumab vedotin (Polivy®) CD79b R/R DLBCL (+ BR) - 1.8 mg/kg per cycle, combined with BR - every 21 days for 6 cycles 2019
  1. ALCL anaplastic large cell lymphoma, ALL acute lymphoblastic leukemia, ASCT autologous stem cell transplant, BR bendamustine and rituximab, CR complete remission, CTCL cutaneous T cell lymphoma, DLBCL diffuse large cell lymphoma, HCL hairy cell leukemia, HL Hodgkin lymphoma, NHL non-Hodgkin lymphoma, PTCL peripheral T cell lymphoma, R/R relapsed/refractory